Abstract: A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): wherein R101 represents an acyl residue of an unsaturated higher fatty acid, and R102 represents a hydrogen atom or an acyl residue of an unsaturated higher fatty acid, and pharmaceutically acceptable salts thereof, as an active ingredient.

Abstract: An immunosuppressive agent comprising, as an effective ingredient, at least one compound selected from the group consisting of compounds represented by general formula (1) below and pharmaceutically acceptable salts thereof: 1

Abstract: Novel sulforhamnosylacylglycerol derivatives represented by General Formula (1): where R101 represents an acyl residue of a higher fatty acid and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid. The derivatives represented by General formula (1) are useful as, a DNA polymerase inhibitor and an anticancer agent.

Abstract: Peptides having, as constitutive amino acids, (1) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; (2) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 3 valine residues, and 5 leucine residues, and having a 3-hydroxydecanoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof; or (3) 4 glutamine residues, 1 glutamic acid residue, 1 serine residue, 2 valine residues, 1 isoleucine residue and 5 leucine residues, and having a 3-hydroxydodec-5-enoyl group bonded, via an amide linkage, to the N-terminal leucine residue thereof. The peptides have an antiviral activity. A strain capable of producing the above peptides and belonging to a new species of genus Pseudomonas.

Abstract: Sulfofucosylacylglycerol derivatives represented by General Formula (1): where R101 represents an acyl residue of a higher fatty acid and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid. The derivatives represented by General formula (1) are useful as a DNA polymerase inhibitor and an anticancer agent.

Abstract: A method for treating a cancer. The cancer excluding an adenocarcinoma and being epithelioma, glioma, sarcoma, melanoma, lymphoma or leukemia; or the cancer is an adenocarcinoma cancer excluding colon cancer, lung cancer and gastric cancer.

Abstract: An anticancer drug includes a compound represented by Formula (1): where R101 represents an acyl moiety of a saturated higher fatty acid, and R102 represents a hydrogen atom or an acyl moiety of a saturated higher fatty acid, and/or a pharmaceutically acceptable salt thereof.

Abstract: An anticancer drug includes a compound represented by Formula (1): where R101 represents an acyl moiety of a saturated higher fatty acid, and R102 represents a hydrogen atom or an acyl moiety of a saturated higher fatty acid, and/or a pharmaceutically acceptable salt thereof.

Abstract: A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1): wherein R101 represents an acyl residue of a higher fatty acid, and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid; and a pharmaceutically acceptable salt thereof. Of the sulfoquinovosylacylglycerol derivatives, &bgr;-sulfoquinovosylacylglycerols are novel compounds. The present invention also relates to pharmaceutical composition comprising a pharmaceutically effective amount of the &bgr;-sulfoquinovosylacylglycerols and/or its pharmaceutically acceptable salt; and a pharmaceutically acceptable excipient. The pharmaceutical composition may be used as an immunosuppressive agent, anticancer agent and DNA polymerase &agr; inhibitor.

Abstract: A method for manufacturing a polyimide sleeve where a polyimide sleeve of a high quality can be manufactured easily with a superior yield. A sleeve of a release resin is fitted on a planished metal core or a core at least whose outer surface is made of a release resin, and a polyimide precursor solution is applied on its outer surface. Next, after generating an imide reaction of the polyimide precursor by heating to form an almost completely cured polyimide sleeve, this polyimide sleeve is removed from the core together with the sleeve of the release resin. Furthermore, the polyimide sleeve is separated from the sleeve of the release resin.

Abstract: An anticancer drug includes a compound represented by Formula (1): 1

Abstract: 1-O-(2-propenyl)-6-O-sulfonylpyranoside represented by the formula wherein R1, R2 and R3 each independently represents an alkyl or substituted silyl group, and R4 represents an alkylsulfonyl or arylsulfonyl group.

Abstract: 1-O-(2-propenyl)-6-deoxy-6-carbonylthiopyranoside represented by the formula wherein R1, R2 and R3 each independently represents an alkyl or a substituted silyl group, and R5 represents a hydrogen atom, or an alkyl or aryl group.

Abstract: A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1): 1

Abstract: Novel sulfofucosylacylglycerol derivatives represented by General Formula (1): 1

Abstract: A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): 1

Abstract: Novel sulforhamnosylacylglycerol derivatives represented by General Formula (1): 1

Abstract: The present invention relates to an opening/closing hinge construction for an electronic and electrical equipment housing. By improving the hinge construction so that the hinge construction between a body case and body cover is contained within the housing, the housing is prevented from being large-sized and the assembling property is enhanced, whereby the whole manufacturing cost including the assembly cost is reduced. The construction is such as to open and close the body case forming an equipment housing by the body cover of cover member, and a hinge sheet having flexibility formed into a sheet form is used for a hinge connection portion. One end of the hinge sheet is fixed to the interior of the body case by using hinge bosses and set screws as a fixed locking end, and the other end is fixed to the inside of the body cover as a movable locking end.

Abstract: An amorphous transformer prevents deformation or deflection caused by the repulsion force between an outer coil and an inner coil and prevents formation of a one-turn-current through a reinforcement member and a coil frame. The amorphous transformer includes amorphous cores, an outer coil and an inner coil, a coil frame and a reinforcement member. The reinforcement member prevents the amorphous core from being deformed inward by the electromagnetic force of the coil, and the frame member and the reinforcement member prevents formation of an electrical closed-loop. Accordingly, the amorphous transformer core is protected from being damaged.

Abstract: A catalytic reactor confining a catalyst in a mid-portion of a tubular housing made up of a pair of shells flanged sideways and welded together. The cross-sectional area of the housing becomes largest in the mid-portion, and the assembled shells define therein a fore-portion diverging towards the mid-portion and an aft-portion converging from the mid-portion. Side flanges of each shell are formed substantially over the entire length of the shell, and the width of the flanges is enlarged in both the fore- and aft-portions. The housing has two coupling flanges welded respectively at the fore- and aft-ends of the housing both to the outer periphery of the shells and to the ends of the side flanges.